This article has no abstract; the first 100 words appear below.
In the United States, antiviral treatment of influenza is recommended as soon as possible in hospitalized patients and in outpatients who are at increased risk for influenza complications or have progressive disease, and it can be considered in non–high-risk patients presenting within 2 days after the onset of illness (early treatment).1,2 The neuraminidase inhibitors oseltamivir, zanamivir, and peramivir have been approved by the Food and Drug Administration (FDA) for the early treatment of uncomplicated influenza. Oseltamivir is recommended for the treatment of influenza in hospitalized patients.1 Neuraminidase inhibitors block the influenza viral surface protein neuraminidase to inhibit release of progeny . . .